A detailed history of Walleye Capital LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 8,500 shares of KURA stock, worth $91,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,500
Previous 12,100 29.75%
Holding current value
$91,800
Previous $249,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $9.22 Million - $11.5 Million
496,284 Added 661.0%
571,365 $11.2 Million
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $143,237 - $187,769
-8,171 Reduced 9.81%
75,081 $1.55 Million
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $506,068 - $887,316
37,710 Added 82.8%
83,252 $1.78 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $1.66 Million - $3.15 Million
-219,351 Reduced 82.81%
45,542 $654,000
Q3 2023

Nov 14, 2023

BUY
$8.44 - $11.86 $1.54 Million - $2.16 Million
182,221 Added 220.41%
264,893 $2.42 Million
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $795,304 - $1.16 Million
82,672 New
82,672 $874,000
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $3.22 Million - $5.21 Million
268,074 New
268,074 $3.66 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $323,665 - $455,902
-20,990 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $437,641 - $627,181
20,990 New
20,990 $438,000
Q1 2019

May 15, 2019

SELL
$13.73 - $16.87 $822,866 - $1.01 Million
-59,932 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$16.65 - $21.85 $997,867 - $1.31 Million
59,932 New
59,932 $1.05 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $722M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.